Time to reperfusion: The critical modulator in thrombolysis and primary angioplasty
暂无分享,去创建一个
[1] C. Lambrew. The national heart attack alert program: A review , 2005, Journal of Thrombosis and Thrombolysis.
[2] E. Antman,et al. Time as an adjunctive agent to thrombolytic therapy , 2005, Journal of Thrombosis and Thrombolysis.
[3] C. Cannon. Time to treatment: A crucial factor in thrombolysis and primary angioplasty , 2004, Journal of Thrombosis and Thrombolysis.
[4] P. Gordon. Primary angioplasty for acute myocardial infarction. , 2001, Medicine and health, Rhode Island.
[5] C. Cannon,et al. Influence of door-to-balloon time on mortality in primary angioplasty results in 3,648 patients in the second national registry of myocardial infarction (NRMI-2) , 1996 .
[6] S. Krall,et al. Effect of continuous quality improvement methods on reducing triage to thrombolytic interval for acute myocardial infarction. , 1995, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[7] H. Krumholz,et al. Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. , 1995, JAMA.
[8] C. Lambrew. Emergency department triage of patients with nontraumatic chest pain , 1995 .
[9] K. Lee,et al. Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group. , 1995, The American journal of cardiology.
[10] R. Califf,et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. , 1995, Circulation.
[11] J Col,et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. , 1995, Circulation.
[12] E. Antman,et al. 755-2 Current Management of ST Elevation Myocardial Infarction and Outcome of Thrombolytic Ineligible Patients: Results of the Multicenter TIMI 9 Registry , 1995 .
[13] J. Kalbfleisch,et al. 715-5 Reteplase vs Alteplase Patency Investigation During Myocardial Infarction Trial (RAPID 2) , 1995 .
[14] G. Reeder,et al. 956-115 Method of Reducing Emergency Room Time to Treatment for Acute Myocardial Infarction , 1995 .
[15] M. Hand. 9-1-1 : rapid identification and treatment of acute myocardial infarction , 1995 .
[16] J. Atkins,et al. 9-1-1: rapid identification and treatment of acute myocardial infarction. National Heart Attack Alert Program Coordinating Committee Access to Care Subcommittee. , 1995, The American journal of emergency medicine.
[17] C. Cannon,et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. , 1994, Journal of the American College of Cardiology.
[18] H. Suryapranata,et al. Limitation of Infarct Size and Preservation of Left Ventricular Function After Primary Coronary Angioplast Compared With Intravenous Streptokinase in Acute Myocardial Infarction , 1994, Circulation.
[19] R. Califf,et al. More on the GUSTO Trial , 1994, Annals of Internal Medicine.
[20] W. Rogers,et al. Comparison of primary angioplasty versus thrombolytic therapy for acute myocardial infarction. Alabama Registry of Myocardial Ischemia Investigators. , 1994, The American journal of cardiology.
[21] J. Mcmanus. Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT) , 1994 .
[22] J. O’Keefe,et al. Primary coronary angioplasty for acute myocardial infarction (the Primary Angioplasty Registry). , 1994, The American journal of cardiology.
[23] C. Cannon,et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. , 1994, Journal of the American College of Cardiology.
[24] E. Braunwald,et al. GUSTO, TIMI and the case for rapid reperfusion. , 1994, Acta cardiologica.
[25] J. Rawles. Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). , 1994, Journal of the American College of Cardiology.
[26] E. Braunwald. The open-artery theory is alive and well--again. , 1993, The New England journal of medicine.
[27] Gusto Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. , 1993, The New England journal of medicine.
[28] B. Gersh,et al. Thrombolysis and Myocardial Salvage Results of Clinical Trials and the Animal Paradigm‐ Paradoxic or Predictable? , 1993, Circulation.
[29] L. Becker,et al. TIMI Perfusion Grade 3 but Not Grade 2 Results in Improved Outcome After Thrombolysis for Myocardial Infarction Ventriculographic, Enzymatic, Electrocardiographic Evidence From the TEAM‐3 Study , 1993, Circulation.
[30] J. Reiber,et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. , 1993, The New England journal of medicine.
[31] J O'Keefe,et al. A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial Infarction , 1993 .
[32] K. Bailey,et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups. , 1993, The New England journal of medicine.
[33] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.
[34] U. Tebbe,et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS) , 1992, Journal of the American College of Cardiology.
[35] David Hunt,et al. ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION , 1992 .
[36] R. Luepker,et al. Consequences of a media campaign focusing on delay in acute myocardial infarction. , 1992, American Journal of Cardiology.
[37] K. Fox,et al. Effect of "fast track" admission for acute myocardial infarction on delay to thrombolysis. , 1992, BMJ.
[38] J. Anderson,et al. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Second Multicenter Thrombolysis Trial of Eminase in Acute Myocardial Infarction. , 1992, Journal of the American College of Cardiology.
[39] F. Sheehan,et al. Does arterial patency 90 minutes following thrombolytic therapy predict 42 day survival , 1991 .
[40] E. Braunwald,et al. Optimizing thrombolytic therapy of acute myocardial infarction. , 1990, Circulation.
[41] J. Anderson,et al. Impact of field-transmitted electrocardiography on time to in-hospital thrombolytic therapy in acute myocardial infarction. , 1990, The American journal of cardiology.
[42] Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.. MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction , 1990, The Lancet.
[43] T. A. S. Group. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin , 1990, The Lancet.
[44] P. Kudenchuk,et al. Myocardial Infarction Triage and Intervention Project--phase I: patient characteristics and feasibility of prehospital initiation of thrombolytic therapy. , 1990, Journal of the American College of Cardiology.
[45] E. Ruiz,et al. An analysis of time delays preceding thrombolysis for acute myocardial infarction. , 1989, JAMA.
[46] J. O’Keefe,et al. Early and late results of coronary angioplasty without antecedent thrombolytic therapy for acute myocardial infarction. , 1989, The American journal of cardiology.
[47] I. Belenkie,et al. Importance of effective, early and sustained reperfusion during acute myocardial infarction. , 1989, The American journal of cardiology.
[48] E. Braunwald,et al. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? , 1989, Circulation.
[49] Sarah Parish,et al. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.
[50] E. Braunwald,et al. Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial. , 1988, The American journal of cardiology.
[51] J. Clem. Thrombolytic Therapy for Acute Myocardial Infarction , 1987, The Lancet.
[52] J. Ritchie,et al. Risk stratification for 1 year survival based on characteristics identified in the early hours of acute myocardial infarction. The Western Washington Intracoronary Streptokinase Trial. , 1986, Circulation.
[53] Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.. EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.
[54] W. Ganz,et al. The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.
[55] H. S. Mueller,et al. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.
[56] W. Ganz. Intracoronary thrombolysis in evolving myocardial infarction. , 1981, Annals of internal medicine.
[57] K. Karsch,et al. Initial experience with transluminal recanalization of the recently occluded infarct‐related coronary artery in acute myocardial infarction — Comparison with conventionally treated patients , 1979, Clinical cardiology.
[58] J. Lowe,et al. The Wavefront Phenomenon of Ischemic Cell Death: 1. Myocardial Infarct Size vs Duration of Coronary Occlusion in Dogs , 1977, Circulation.